rs28934576
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The presence of R273H-P53 conferred the cancer cells with drug resistance not only against the widely used chemotherapeutic agents like cisplatin (CDDP) or 5-flurouracil (5-FU) but also against potent alternative modes of therapy like proteasomal inhibition.
|
30723502 |
2019 |
rs28934576
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results indicate that mutant TP53 G245C and R273H can lead to more aggressive phenotypes and enhance cancer cell malignancy, which further uncover TP53 function in carcinogenesis and might be useful in clinical diagnosis and therapy of TP53 mutant cancers.
|
30126368 |
2018 |
rs28934576
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Expression of mutp53-R273H also makes cancer cells more sensitive to DNA2 depletion or DNA2 inhibitors.
|
28439015 |
2017 |
rs28934576
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
R273H mutation of p53 has been closely implicated in human cancer.
|
26898459 |
2016 |
rs28934576
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Targeting CD24 provides a strategy to enhance mutant p53-restoring therapies, especially in patients with TP53(R273H) prostate cancer.Clin Cancer Res; 22(10); 2545-54.©2015 AACR.
|
26712693 |
2016 |
rs28934576
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
|
26181206 |
2015 |
rs28934576
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy.
|
24677579 |
2014 |
rs28934576
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
These activities are attributable to mutant p53(R273H) gain of function and might underlie its well-documented oncogenic nature in human cancer.
|
22899716 |
2012 |
rs28934576
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Many p53 cancer mutants, including the hot spot mutations (R175H, R248W and R273H), not only lose p53-dependent tumor-suppressor activities, but also acquire new oncogenic activities to promote cancer.
|
19881536 |
2010 |
rs28934576
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
To elucidate the nature of the gain of function, we introduced the most common p53 cancer mutations (R248W and R273H) independently into the humanized p53 knock-in (HUPKI) allele in mice.
|
17417627 |
2007 |
rs28934576
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
R273H expression in p53-null cancer cell SK-OV-3 and Saos-2 did not significantly affect cell invasion and migration activities.
|
17636407 |
2007 |
rs28934576
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Neither dicoumarol nor curcumin dissociated the complexes of NQO1 and the human cancer hot-spot p53 R273H mutant and therefore did not induce degradation of this mutant.
|
15809436 |
2005 |